PanGIA Biotech, a biotechnology company developing liquid biopsy technology that is scalable for global impact, is preparing to launch new clinical studies in multi-cancer early detection using the PanGIA Liquid Biopsy Platform. This announcement comes as the company wraps finalizes its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy.
“The PanGIA urine based true liquid biopsy technology has been developed for global impact by diagnosing, monitoring, and managing cancers earlier to save lives using urine as the sample type to create vastly improved availability and scalability in cancer diagnostics,” says PanGIA Biotech CEO Holly Magliochetti.
In 2020, the company received IRB approval and launched a novel AI integrated urine-based liquid biopsy study. The company immediately began recruiting urologists in U.S.-based academic as well as large and small group community practices to enroll men who were scheduled for prostate biopsy. Results of the study are pending publication.
Further Reading: Automated Liquid Biopsy Detects Brain Tumor Cells in Children
“Based on the high sensitivity and high specificity of the PanGIA prostate study, PanGIA Biotech is now preparing to significantly expand the platform by launching follow-on studies in ten additional cancer types,” says Tricia Schumann, chief investment officer of PanGIA Biotech.
Additional cancer types in the PanGIA follow-on study will include breast, ovarian, lung, renal, bladder, colorectal, stomach, pancreas, liver, and brain. The company will begin recruiting experienced medical professionals across the United States as clinical study sites as well as listing the study on ClinicalTrials.gov.
PanGIA Biotech intends to launch the expanded study in mid-2024. Interested researchers may contact the company for additional information.